Sana Biotechnology (SANA) shares more than doubled in recent Wednesday trading, a day after the company reported positive initial results from a study involving its hypoimmune technology in type 1 diabetes treatment.
On Wednesday, TD Cowen upgraded its rating on the stock to buy from hold.
Intraday volume in Sana topped 88.3 million shares Wednesday versus the daily average of 2.01 million shares.
Sana said late Tuesday the study showed that its hypoimmune technology enabled the transplanted islet cells to avoid rejection and produce insulin without immunosuppression.
Price: 4.21, Change: +2.56, Percent Change: +155.15